Find the risk before the event. Then move it.

Sustained blood pressure elevation is silent and progressive - and it is the single largest treatable driver of stroke, heart attack, heart failure, and kidney disease. The aim of management is to get to target consistently, not to chase a perfect reading on a single day.

Diagnosis: confirmed by repeated readings under standardised conditions, often supplemented by home blood pressure monitoring or 24-hour ambulatory monitoring to rule out white-coat hypertension and identify nocturnal patterns.

Target ranges: typically <140/90 for most adults, with tighter targets (<130/80) for men with diabetes, established cardiovascular disease, or high calculated risk. Targets are individualised based on age, comorbidity, and tolerance.

First-line lifestyle: sodium reduction (<5 g/day), weight loss where overweight, regular aerobic exercise, alcohol moderation, and adequate sleep. Lifestyle alone can lower systolic blood pressure by 5-15 mmHg in motivated patients.

Medications: ACE inhibitors, ARBs, calcium channel blockers, and thiazide diuretics are first-line. Choice depends on comorbidity (diabetes, kidney function, prior cardiac events) and tolerability. Combination therapy is often more effective than monotherapy at higher doses.

Monitoring: home blood pressure log, repeat in-clinic reading at 4-6 weeks, then 3-monthly until stable. Annual review of kidney function, electrolytes, and overall cardiovascular risk.

Effectiveness: every 10 mmHg reduction in systolic blood pressure reduces major cardiovascular events by roughly 20% in men at elevated risk.

LDL cholesterol is the lipid metric most strongly tied to atherosclerosis. The level at which intervention becomes worthwhile depends on overall cardiovascular risk - not LDL alone, and not the lab report's generic reference range.

Workup: full fasting lipid profile (total cholesterol, LDL, HDL, triglycerides), and where indicated apolipoprotein B (the better target in men with metabolic syndrome or borderline LDL) and lipoprotein(a) (genetically determined, measured once in a lifetime - see our dedicated Lp(a) page).

Target LDL: <3.0 mmol/L for low-risk men; <2.6 mmol/L for moderate risk; <1.8 mmol/L for high risk or established disease; <1.4 mmol/L for very high risk (e.g. prior heart attack, diabetes with organ damage, familial hypercholesterolaemia).

Lifestyle: Mediterranean-style dietary pattern is the most evidence-based - vegetables, legumes, fish, olive oil, nuts, whole grains, with reduced ultra-processed food, added sugar, and saturated fat. Regular aerobic exercise modestly improves HDL and triglycerides.

Statins: first-line lipid-lowering therapy for men whose calculated risk justifies treatment. Most men tolerate statins well; muscle symptoms occur in a minority and are usually manageable with dose adjustment or rotation to a different statin.

Non-statin options: ezetimibe (added when statin alone doesn't reach target), PCSK9 inhibitors (for very high-risk men or statin-intolerant), bempedoic acid where available.

Monitoring: lipid recheck at 6-12 weeks after starting therapy, liver enzymes if symptoms, then annually once stable. Treatment is long-term: the benefit comes from sustained LDL reduction over years.

Read our full risk-stratified LDL targets guide for the specific numbers, how risk is calculated, and what the right plan looks like for your band: /cardiac-care/lipid-management.

Standard risk calculators (Framingham, ASCVD, SCORE2) put most middle-aged men in an intermediate band that the calculator alone cannot resolve. CT coronary imaging cuts through this ambiguity by showing the disease itself - plaque is either there or it is not - and reclassifies a meaningful share of intermediate-risk men, allowing prevention to be targeted rather than averaged.

CT coronary artery calcium score (CAC, Agatston): a quick, low-radiation, no-contrast scan that quantifies calcified plaque in your coronary arteries. Scored 0, 1-99, 100-399, or 400+. A zero score in a man over 45 typically defers statin therapy; a meaningful score reclassifies risk upward and triggers earlier, more aggressive prevention.

CT coronary angiogram (CTCA): contrast-enhanced CT that images the coronary lumen and the plaque itself, including non-calcified (soft) plaque that calcium scoring misses. Preferred in younger men with strong family history, when symptoms warrant direct visualisation, and as a non-invasive alternative to invasive angiography. Large trials (SCOT-HEART, PROMISE) have shown CTCA-guided care reduces non-fatal myocardial infarction over 5 years by getting the right men onto preventive therapy earlier.

How a CT result changes the plan: a CAC of zero may defer statin therapy and shift the recheck to 5 years; a CAC of 150 in the same man triggers statin therapy with a tighter LDL target, blood-pressure intensification and consideration of aspirin; non-calcified plaque on CTCA in a younger man with strong family history is treated as high-risk even when CAC is zero.

Direct-access ordering at Hisential: our MMC-registered medical team orders CAC and CTCA directly at partner hospitals without requiring a prior cardiologist consultation. Faster, lower total cost, and integrated into your wider plan. Specialist cardiology review is coordinated by your concierge if findings warrant it. See our dedicated CT coronary imaging page: /cardiac-care/ct-coronary-imaging.

Panel lipid standard tidak mengesan dua isyarat risiko penting. Apolipoprotein B (ApoB) mengira bilangan sebenar partikel aterogenik, bukan sekadar jisim kolesterol; pada lelaki dengan sindrom metabolik atau LDL sempadan, ApoB boleh tinggi walaupun LDL kelihatan normal. Lipoprotein(a) ialah partikel yang ditentukan secara genetik yang secara bebas meningkatkan risiko serangan jantung dan strok sepanjang hayat pada kira‑kira 1 dalam 5 orang – dan hampir tidak pernah diukur dalam amalan umum Malaysia.

ApoB dan nisbah ApoB/ApoA1 ditambah pada penilaian apabila ciri metabolik hadir, atau apabila LDL standard dan risiko terhitung memberikan isyarat yang berbeza. Mereka menjadi sasaran rawatan apabila panel standard dan ApoB tidak sepadan.

Lp(a) diukur sekali seumur hidup. Nilainya sendiri tidak berubah secara signifikan dengan gaya hidup atau statin, tetapi keputusan tinggi mengeratkan setiap sasaran kardiovaskular lain – terutama LDL – dan memicu saringan lanjutan pada saudara sepupu pertama. Lihat halaman Lp(a) khusus kami: /cardiac-care/lipoprotein-a.

Diabetes dan pra-diabetes secara signifikan mempertingkatkan risiko kardiovaskular – lelaki dengan diabetes jenis 2 mempunyai kira‑kira dua kali risiko serangan jantung dan strok sepanjang hayat. Mengenal pasti dan merawat disfungsi metabolik lebih awal mengurangkan hasil mikrovasular dan makrovasular.

Saringan: HbA1c, glukosa puasa, insulin puasa bila diperlukan, BMI, lilit pinggang, dan tekanan darah bersama-sama mengenal pasti lelaki dalam spektrum dari metabolisme normal, pra-diabetes hingga diabetes jenis 2.

Pengurusan pra-diabetes: perubahan gaya hidup sangat berkesan – perubahan diet berstruktur dan aktiviti tetap dapat mengurangkan kemajuan ke diabetes jenis 2 sebanyak ~58 % pada pesakit yang bermotivasi. Metformin dipertimbangkan pada lelaki pra-diabetes berisiko tinggi.

Diabetes jenis 2 yang sedia ada: sasaran HbA1c disesuaikan (biasanya <7 % untuk kebanyakan lelaki, lebih longgar pada pesakit lebih tua atau yang mempunyai komorbiditi). Ubat moden termasuk agonis reseptor GLP‑1 (semaglutide, liraglutide) dan inhibitor SGLT2 (empagliflozin, dapagliflozin) mempunyai manfaat kardiovaskular khusus di luar kawalan glukosa dan lebih disukai untuk lelaki dengan penyakit kardiovaskular sedia ada atau berisiko tinggi. Lihat penjagaan diabetes.

Pengurangan lemak visceral: penurunan berat badan 5‑10 % secara signifikan mengubah tekanan darah, lipid, glukosa puasa, dan penanda keradangan. Angka yang disasarkan harus berkelanjutan, bukan dramatik. Lihat penurunan berat badan untuk program berstruktur.

Koordinasi: ramai lelaki mendapat manfaat daripada pelan terkoordinasi yang merangkumi tekanan darah, lipid, glukosa, dan berat badan secara serentak – concierge kesihatan peribadi anda memastikan semua ini tidak diurus secara berasingan.

Penilaian semula: setiap 3 bulan semasa membuat perubahan, kemudian setiap 6‑12 bulan setelah stabil.

Intervensi berasaskan bukti yang benar‑benar mempengaruhi hasil kardiovaskular juga merupakan yang paling membosankan – dan paling berkuasa. Peranan protokol gaya hidup ialah memfokuskan usaha pada beberapa intervensi yang betul‑betul mengubah risiko, bukannya menyebar usaha secara tipis.

Berhenti merokok: faktor risiko kardiovaskular yang paling besar boleh dipulihkan. Berhenti pada mana‑mana usia mengurangkan risiko secara signifikan dalam beberapa bulan hingga tahun. Sokongan berhenti berstruktur, termasuk pengganti nikotin dan farmakoterapi bila perlu, merupakan sebahagian daripada konsultasi jantung pertama bagi lelaki yang merokok.

Latihan aerobik dan tahanan: 150 minit seminggu aktiviti aerobik sederhana plus 2‑3 sesi tahanan seminggu memberi kebanyakan manfaat kardiovaskular. Lebih banyak lebih baik hingga batas tertentu; peningkatan terbesar ialah beralih dari tidak aktif ke konsisten.

Pola pemakanan gaya Mediterranean: sayur-sayuran, kekacang, kacang, ikan, minyak zaitun, dengan makanan ultra-proses dan gula tambahan yang terhad. Pola diet dengan bukti kardiovaskular terkuat. Superfood khusus, suplemen, dan diet penyingkiran kebanyakannya tidak relevan.

Tidur: 7‑9 jam adalah sasaran umum. Apnea tidur – biasa, sering tidak dikenali pada lelaki dengan adipositi pusat, hipertensi, atau tidur tidak menyegarkan – secara signifikan meningkatkan risiko kardiovaskular dan patut disaring jika terdapat petunjuk (dengkur kuat, apnea yang terlihat, keletihan siang).

Alkohol: tiada tahap alkohol yang melindungi jantung pada peringkat populasi. Bagi lelaki yang minum, pengambilan sederhana (≤14 unit seminggu, diedarkan pada beberapa hari, dengan hari tanpa alkohol) mengurangkan risiko.

Tekanan dan kesihatan mental: tekanan kronik meningkatkan kortisol, tekanan darah, dan penanda keradangan. Menangani ia melalui pendekatan berstruktur (senaman, tidur, hubungan sosial, sokongan profesional bila perlu) merupakan bahagian penjagaan kardiovaskular.

Apa yang kebanyakannya mengalihkan perhatian: kebanyakan suplemen antioksidan, protokol puasa rumit yang dijalankan tanpa indikasi metabolik, penilaian perubatan fungsi yang sangat mahal yang menghasilkan banyak nombor tetapi tiada pelan.